What we found on the web about AlloMap®
Success With AlloMap Molecular Expression Testing
XDx, a molecular diagnostics company, has announced its AlloMap® molecular expression test was the subject of presentations and discussions at the American Transplant Congress ...
Surgical Innovations, Blood Test Replaces Heart Biopsy
Using these 11 genes and another 9 for control, the company developed the AlloMap™ molecular expression test – a tiny chip with 20 genes used to evaluate a cardiac patient's ...
XDx's AlloMap(R) Gene Expression Test Cleared By U.S. FDA For Heart ...
XDx, Inc. has received market clearance from the U.S. Food and Drug Administration (FDA) for AlloMap® Molecular Expression Testing. The AlloMap Test is a noninvasive, multi-gene ...
AlloMap - Organ Transplant: Support Group at WebMD
Been a long time since I have posted on this board. I have recently taken the AlloMap test for heart transplant rejection, in addition to my regular heart biopsy.
Entry added by Creative Administrator
Creative Administrator also edited:
Here is what users have to say about AlloMap®

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention AlloMap®
Cash is life in the life sciences
San Francisco Business Journal
The 8-year-old company’s AlloMap won FDA clearance and Medicare reimbursement for a $3,000 noninvasive blood test that determines the potential risk of heart transplant rejection. But the global financial crisis caused the company to pull o...
Blood test OK’d for heart transplant rejection
MSNBC
The AlloMap test had been previously approved in 2005 under federal laws that govern clinical labs. But Yee said it is being used at fewer than half of the nation's heart transplant centers, and that FDA clearance should speed its adoption ...
World Economic Forum announces Technology Pioneers 2006
World Economic Forum
... is to construct a synthetic microbe for use in the production of the anti-malarial drug artemisinin to meet a critical need in the developing world. § XDx, South San Francisco, CA, USA - XDx has developed and launched a technology calle...